ReShape Lifesciences Inc. (RSLS) Misses Q3 EPS by 77c

ReShape Lifesciences Inc. (NASDAQ: RSLS) reported Q3 EPS of ($1.06), $0.77 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $360 thousand versus the consensus estimate of $310 thousand.

For earnings history and earnings-related data on ReShape Lifesciences Inc. (RSLS) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
• Compass Point Starts Gorilla Tech Group/ (GRRR) at Buy